Netarsudil mesylate

Drug Profile

Netarsudil mesylate

Alternative Names: AR-13224; AR13324; Netarsudil ophthalmic solution - Aerie Pharmaceuticals; Rhopressa

Latest Information Update: 18 May 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Duke University Medical Center
  • Developer Aerie Pharmaceuticals
  • Class Antiglaucomas; Small molecules
  • Mechanism of Action Connective tissue growth factor inhibitors; Norepinephrine plasma membrane transport protein inhibitors; Rho-associated kinase inhibitors; Transforming growth factor beta type II receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Preregistration Glaucoma; Ocular hypertension
  • Preclinical Neurological disorders

Most Recent Events

  • 16 Aug 2017 Cornea Research Foundation of America plans a phase III trial for Ocular hypertension (Prevention) (NCT03248037)
  • 12 Jul 2017 Aerie Pharmaceuticals plans a phase II trial for Primary open angle glaucoma and Ocular hypertension (Opthalmic) (NCT03233308)
  • 16 May 2017 The US FDA assigns PDUFA action date of 28 February 2018 for Netarsudil mesylate ophthalmic solution for Glaucoma and Ocular hypertension
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top